Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Drug trial sits at the center of this dementia and brain health question.
Multiple clinical trials for Alzheimer’s disease are actively enrolling patients, representing a significant expansion in treatment research and hope for individuals facing cognitive decline. Among the most notable is an international prevention trial led by Washington University School of Medicine in St. Louis, which has begun recruiting young adults at high genetic risk for Alzheimer’s disease to determine whether intervening early—before symptoms appear—can prevent or delay disease onset entirely.
This landmark shift in how researchers approach Alzheimer’s reflects a fundamental change in clinical strategy: rather than waiting for cognitive symptoms to develop, scientists are now testing whether stopping the underlying molecular changes in the brain can halt the disease before it manifests. The broader landscape tells an encouraging story about the scale of Alzheimer’s research. The National Institute on Aging is currently supporting 466 active clinical trials focused on Alzheimer’s disease and related dementias, testing diverse approaches from new medications to preventive strategies and cognitive interventions. These trials span multiple patient populations—from cognitively normal individuals with biomarker evidence of disease to those with mild cognitive impairment and early Alzheimer’s disease—creating a comprehensive research pipeline that addresses the disease across its entire progression.
Table of Contents
- Why Are Clinical Trials Expanding and What Does Patient Enrollment Mean?
- What Makes Prevention Trials Different From Treatment Trials and Why Does It Matter?
- How Do Current Drug Trials Approach Alzheimer’s Across Different Disease Stages?
- What Should Patients and Families Know About Participating in Clinical Trials?
- What Are the Biggest Challenges That Current Alzheimer’s Trials Face?
- How Are Trial Sites and Patient Networks Expanding to Support More Research?
- What Can We Expect From Alzheimer’s Research Over the Next Few Years?
- Conclusion
Why Are Clinical Trials Expanding and What Does Patient Enrollment Mean?
Clinical trials expand when promising research in laboratories shows potential benefit for human patients, and enrollment is the critical step that validates whether those lab findings translate to real-world outcomes. When a trial like Washington University’s prevention study begins enrolling patients, it signals that preliminary evidence has convinced the scientific community and regulatory authorities that the approach is safe and worth testing systematically. Enrollment also means that researchers are actively recruiting from the patient population they’re studying, which requires coordinating across multiple medical centers, screening thousands of potential participants, and matching them to specific inclusion criteria—a logistically complex but essential process.
The enrollment process itself provides early signals about whether a trial has identified a genuinely important research question. Cognition Therapeutics’ Phase 2 START study for zervimesine (a compound called CT1812) has reached 75% enrollment with approximately 540 participants, measuring how an oral treatment works in individuals with elevated amyloid plaques and mild cognitive impairment or early Alzheimer’s disease. This level of enrollment suggests that trial sites are able to identify eligible patients, that patients are willing to participate in the research, and that the medical community views the drug as a credible candidate worth testing—though reaching 75% enrollment does not guarantee the drug will ultimately be approved or effective.
What Makes Prevention Trials Different From Treatment Trials and Why Does It Matter?
Prevention trials fundamentally differ from treatment trials in their target population and what constitutes success. A treatment trial enrolls people who already have cognitive symptoms or an Alzheimer’s diagnosis and measures whether a drug slows decline or improves function. A prevention trial, by contrast, typically enrolls cognitively normal individuals who have biomarker evidence (usually amyloid accumulation detected on PET scans or in cerebrospinal fluid) showing that the underlying pathology of Alzheimer’s disease is developing silently in their brains. The goal is to prevent symptoms from ever appearing—a far more ambitious target that requires following patients for years and comparing disease emergence rates between treatment and placebo groups.
The practical limitation of prevention trials is that they demand exceptional patience and commitment from participants and researchers alike. Washington University’s prevention trial may need to follow participants for a decade or longer before having clear evidence that the treatment prevented cognitive decline, because it requires waiting to see whether untreated individuals develop symptoms while treated individuals remain cognitively normal. This long timeline means fewer prevention trials are launched compared to treatment trials, and when they do launch successfully, it attracts significant attention. Additionally, prevention trials typically require participants to undergo amyloid PET scans or lumbar punctures to confirm they have evidence of preclinical Alzheimer’s disease, which are invasive or costly procedures that limit the pool of willing participants.
How Do Current Drug Trials Approach Alzheimer’s Across Different Disease Stages?
alzheimer‘s drug development now spans three distinct disease stages: preclinical (no cognitive symptoms but biomarker evidence of disease), mild cognitive impairment (subtle cognitive changes noticed by the individual or family), and early to moderate dementia (more pronounced cognitive decline affecting daily function). This staged approach recognizes that Alzheimer’s is a progressive disease and that intervention timing matters—drugs that work for early-stage disease may not work the same way in moderate dementia, and prevention strategies target a different mechanism than cognitive support in symptomatic patients. The trials expected to deliver results in 2026 illustrate this diversity.
The TRAILRUNNER-ALZ 1 study testing remternetug involves over 1,600 patients and appears focused on symptomatic disease. AriBio’s AR1001 Phase 3 trial enrolls more than 1,500 participants in a mid-stage disease population. Cognito Therapeutics’ SPECTRIS headset trial with 670 participants finishing in June 2026 represents a novel non-pharmacologic approach. This variety means that families and patients have multiple potential pathways being tested simultaneously, though it also means the field remains fragmented and that a breakthrough in one approach may not help all patient populations equally.
What Should Patients and Families Know About Participating in Clinical Trials?
Clinical trial participation offers both significant opportunities and legitimate risks that deserve careful consideration. For individuals who participate, trials provide access to investigational drugs years before they might become available commercially, close medical monitoring by experienced research teams, and the knowledge that their participation advances the field. For families, trials sometimes provide reassurance that they’re doing everything possible and may offer genetic counseling or biomarker screening as part of the study. However, participating in a clinical trial carries important tradeoffs.
Participants must commit to frequent clinic visits, often including PET scans, MRIs, lumbar punctures, or other procedures that carry their own small risks. They may receive a placebo instead of the active drug, meaning they forgo access to an investigational treatment. Trials have strict eligibility criteria—age ranges, cognitive requirements, biomarker status, medication restrictions, and comorbidity limits—that exclude many interested individuals. For someone seeking answers or hoping for treatment options, learning they don’t qualify for any available trial can be emotionally difficult. Additionally, trial results take years to appear, and negative results can disappoint families who had hoped the drug would help their loved ones.
What Are the Biggest Challenges That Current Alzheimer’s Trials Face?
One fundamental challenge facing nearly all Alzheimer’s trials is the problem of progression rates and heterogeneity: not all individuals with the same biomarker profile progress at the same rate, and not all individuals respond to treatment the same way. Some cognitively normal people with amyloid accumulation may never develop symptoms, while others progress to cognitive impairment within a few years. This variability means larger sample sizes are required to detect treatment effects, which explains why modern trials like TRAILRUNNER-ALZ 1 enroll over 1,600 patients rather than several hundred. The larger the trial, the more expensive it becomes and the longer it takes to complete.
Another critical challenge is retaining participants over the years or decades required for meaningful results. Dropouts from trials occur for many reasons: patients move, develop competing medical issues, cannot manage the time commitment, or simply lose faith in the study as years pass without visible progress. High dropout rates can compromise the statistical power of a trial and introduce bias if certain types of patients are more likely to drop out than others. The 75% enrollment rate of the Cognition Therapeutics zervimesine trial represents progress toward full enrollment, but it also signals that a quarter of planned participants remain to be recruited—and recruitment challenges remain common across the Alzheimer’s research landscape.
How Are Trial Sites and Patient Networks Expanding to Support More Research?
To support the 466 active NIA-funded Alzheimer’s clinical trials, a network of research centers, academic medical centers, and private neurology practices has grown substantially. These sites share best practices in participant recruitment, provide standardized training to research staff, and collaborate through networks that make participant referrals easier when one trial closes or when a participant doesn’t fit one study but might qualify for another. Washington University’s international prevention trial, by virtue of being international, requires collaboration across countries and healthcare systems, which adds logistical complexity but also broadens the potential participant pool.
A notable practical limitation is that rural and underserved communities remain underrepresented in Alzheimer’s trials, partly because research infrastructure is concentrated in urban centers and academic medical hubs. Individuals in rural areas may need to travel several hours to participate, making consistent attendance difficult. This geographic limitation means that trial results may not fully represent how treatments work across diverse populations and settings, and it creates inequities in who has access to cutting-edge research.
What Can We Expect From Alzheimer’s Research Over the Next Few Years?
The timeline of trials expected to report results in 2026—including the completion of the SPECTRIS headset trial in June and the maturation of data from multiple large Phase 3 studies—suggests that the field is moving toward concrete answers about which approaches most effectively slow or prevent cognitive decline. If even one or two of these trials demonstrates clear benefit, regulatory approvals could follow within months, potentially expanding treatment options for thousands of patients. The prevention trial initiated by Washington University represents a longer-term commitment but could fundamentally shift Alzheimer’s management if it demonstrates that early intervention prevents disease onset.
The future of Alzheimer’s research appears to rest on three converging trends: earlier and more accurate identification of at-risk individuals through biomarker screening, a growing pipeline of drugs targeting different pathological mechanisms, and a willingness to test prevention strategies in younger, cognitively normal populations. This combination suggests that within a decade, our approach to Alzheimer’s management could shift from treating symptoms in advanced disease to preventing disease in at-risk individuals decades before symptoms would have appeared. The trials enrolling patients today will provide the evidence base for that transformation.
Conclusion
The expansion of clinical trial enrollment across multiple Alzheimer’s prevention and treatment studies represents both scientific progress and realistic hope for a disease that has long seemed intractable. Washington University’s prevention trial and the growing landscape of 466 NIA-supported trials signal that researchers are diversifying their approach, testing drugs at different disease stages, and taking seriously the possibility that early intervention may prevent disease onset. These trials require commitment from participants, navigate complex scientific and logistical challenges, and demand years before producing results—but they represent the most direct path to developing treatments that could transform how Alzheimer’s disease is managed.
If you or a family member is concerned about cognitive decline or at risk for Alzheimer’s disease, discussing these clinical trial opportunities with your physician is a reasonable next step. Not every person will qualify for every study, but the expanding number of active trials means that options exist for many patient populations. The progress seen in recent years—from the first amyloid-targeting drug approvals to these new prevention trials—demonstrates that Alzheimer’s research has momentum and that participation in clinical research, whether as a patient or a family member considering research participation, remains one of the most direct ways to advance the field toward better treatments and prevention strategies.
You Might Also Like
- Women Face Higher Alzheimer’s Risk According to New Study Findings
- Popular Supplement Now Linked to Alzheimer’s Protection in New Research
- New Study Reveals Why Women Face Higher Alzheimer’s Risk Than Men
For more, see Alzheimer’s Association — medical tests.
